NON RARE IN EUROPE: Age-related macular degeneration Advocacy Hub | UniteRare

At a Glance

Live from database

💊

1FDA treatments

💰

2Open funds

Regulatory Watchboard

No FDA or trial events recorded yet for NON RARE IN EUROPE: Age-related macular degeneration.

Financial Assistance

2 programs

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Copay cards

Copay Assistance2

EYLEA

Regeneron

OpenContact for detailsApply ↗

EYLEA HD

Regeneron

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Eylea

(aflibercept)Orphan drugstandard

Regeneron Pharmaceuticals, Inc.

Vascular Endothelial Growth Factor Inhibitor [EPC]

12.1 Mechanism of Action Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for NON RARE IN EUROPE: Age-related macular degeneration.
Search all trials →

Search clinical trials for NON RARE IN EUROPE: Age-related macular degeneration →

Recent News & Research

No recent news articles indexed yet for NON RARE IN EUROPE: Age-related macular degeneration.
Search PubMed for NON RARE IN EUROPE: Age-related macular degeneration →

Browse all NON RARE IN EUROPE: Age-related macular degeneration news →

Specialist Network

No specialists currently listed for NON RARE IN EUROPE: Age-related macular degeneration.

View all NON RARE IN EUROPE: Age-related macular degeneration specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰